"Recently, the FDA took an important first step in acknowledging the need to introduce more competition by prioritizing generic applications where there is no competition. This effort will give patients better access to affordable treatments," said John Rother, executive director of the Campaign for Sustainable Rx Pricing. Read More
“Today’s AARP report provides new evidence that drug companies are raising prescription drug prices on patients indiscriminately. Specialty and branded drugs alike are going up six times faster than inflation. The exorbitant increases make health care more expensive for families, taxpayers, and job creators and put a major strain on federal and state governments. It's going to take market-based policy solutions to deal with this unsustainable trend.” Read More
“Prescription drug cost hikes are not limited to companies run by people like Martin Shkreli; they are commonplace in the pharmaceutical industry. This issue transcends political party lines because consumers, patients, and public programs across the country simply cannot afford higher prices for medication." Read More
“Again and again, drug companies like Pfizer raise prices of prescriptions that have already been on the market for years which hurts patients trying to make ends meet and public programs dealing with difficult budgets. These increases, compounded year after year, are simply unsustainable. It’s not about innovation or research; it’s price gouging.” Read More
This afternoon, the Centers for Medicare & Medicaid Services took an important step in the drug pricing conversation by introducing a tool that will increase transparency. To develop realistic market-based solutions to unsustainable drug prices requires that everyone focus on value and transparency in drug pricing, and this latest effort from CMS is a positive step.” Read More
“For a breakthrough medication to be effective, it needs to be affordable, yet drug makers fail time and time again to abide by this fundamental principle. The Campaign commends the Senate Special Committee on Aging for challenging the pharmaceutical industry on the irresponsible pricing strategies that deliberately deny patients and consumers access to affordable treatments." Read More
“This latest analysis from the Kaiser Family Foundation paints a troubling picture for the future of the Medicare Part D program and beneficiaries who rely on access to affordable treatments." Read More
“As we all focus on how to ensure patients get the medications they need at an affordable price, we commend Senators Wyden and Grassley for undertaking this important investigation and for raising awareness around this rapidly growing issue for both sides of the aisle." Read More
"With presidential candidates on both sides of the aisle actively talking about unsustainable prescription drug pricing, the issue is clearly bigger than politics — it’s about protecting American families and ensuring they can access the critical treatments they need at prices they can afford." Read More
Report: Prescription Drug Spending Tops Year-Over-Year Price Growth for Major… Read More
Exorbitant price tags associated with breakthrough treatments illustrate the broader challenges ahead for the U.S. health care system if excessive drug pricing is not addressed head on. Read More
As the 2016 presidential race heats up, prominent candidates are beginning to unveil comprehensive plans to address soaring prescription drug costs and the harmful impact their price tags have on Americans. Read More